All In Biotech

Drug Trial Radar · NCT03793166

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 1,175 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,175

Planned (sponsor's estimate)

Start

Jun 7, 2019

Primary completion

Mar 1, 2028

Study completion Mar 1, 2028

Sponsor

Sponsor type
NIH
First posted
Jan 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase III trial compares the usual treatment (treatment with ipilimumab and nivolumab followed by nivolumab alone) to treatment with ipilimumab and nivolumab, followed by nivolumab with cabozantinib in patients with untreated renal cell carcinoma that has spread to other parts of the body. The addition of cabozantinib to the usual treatment may make it work better. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known how well the combination of cabozantinib and nivolumab after initial treatment with ipilimumab and nivolumab works in treating patients with renal cell cancer that has spread to other parts of the body.

Conditions

  • Clear Cell Renal Cell Carcinoma
  • Metastatic Malignant Neoplasm in the Bone
  • Metastatic Malignant Neoplasm in the Lymph Nodes
  • Metastatic Malignant Neoplasm in the Soft Tissue
  • Metastatic Malignant Neoplasm in the Viscera
  • Rhabdoid Tumor of the Kidney
  • Sarcomatoid Renal Cell Carcinoma
  • Stage III Renal Cell Cancer AJCC v8
  • Stage IV Renal Cell Cancer AJCC v8

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood and urine sample collection

  • Bone ScanProcedure

    Undergo bone scan

  • CabozantinibDrug

    Given PO

  • Computed TomographyProcedure

    Undergo CT scan

  • IpilimumabBiological

    Given IV

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • NivolumabBiological

    Given IV

  • Quality-of-Life AssessmentOther

    Ancillary studies

  • Questionnaire AdministrationOther

    Ancillary studies

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: From registration to date of death from any cause for non-randomized patients, from time of randomization until death from any cause for randomized patients, assessed up to 5 years

Locations

859 sites in 2 countries. Site status is shown where the registry gives one.

  • University of South Alabama Mitchell Cancer Institute

    Mobile, Alabama

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska

  • Anchorage Radiation Therapy Center

    Anchorage, Alaska

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska

  • Alaska Women's Cancer Care

    Anchorage, Alaska

  • Anchorage Oncology Centre

    Anchorage, Alaska

  • Katmai Oncology Group

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Fairbanks Memorial Hospital

    Fairbanks, Alaska

  • Kingman Regional Medical Center

    Kingman, Arizona

  • Cancer Center at Saint Joseph's

    Phoenix, Arizona

  • Highlands Oncology Group - Fayetteville

    Fayetteville, Arkansas

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas

  • CHI Saint Vincent Cancer Center Hot Springs

    Hot Springs, Arkansas

  • Highlands Oncology Group - Rogers

    Rogers, Arkansas

  • Highlands Oncology Group

    Springdale, Arkansas

  • Kaiser Permanente-Anaheim

    Anaheim, California

  • Mission Hope Medical Oncology - Arroyo Grande

    Arroyo Grande, California

  • PCR Oncology

    Arroyo Grande, California

  • Kaiser Permanente-Baldwin Park

    Baldwin Park, California

  • Kaiser Permanente-Bellflower

    Bellflower, California

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • Community Cancer Institute

    Clovis, California

  • University Oncology Associates

    Clovis, California

  • Kaiser Permanente-Fontana

    Fontana, California

  • Kaiser Permanente South Bay

    Harbor City, California

  • Kaiser Permanente-Irvine

    Irvine, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California

  • Kaiser Permanente West Los Angeles

    Los Angeles, California

  • Kaiser Permanente-Ontario

    Ontario, California

  • Kaiser Permanente - Panorama City

    Panorama City, California

  • Kaiser Permanente-Riverside

    Riverside, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • Kaiser Permanente-Rio San Diego

    San Diego, California

  • Kaiser Permanente-San Diego Zion

    San Diego, California

  • Sharp Memorial Hospital

    San Diego, California

  • Naval Medical Center -San Diego

    San Diego, California

  • UCSF Medical Center-Mission Bay

    San Francisco, California

Showing 40 of 859 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.